基于网络药理学和实验验证探究桃红饮治疗动脉粥样硬化作用机制  

Exploring Mechanism of Action of Taohong Decoction in Treating Atherosclerosis Based on Network Pharmacology and Experimental Validation

作　　者：郭长学 赵晓乐 李小伟 GUO Changxue;ZHAO Xiaole;LI Xiaowei(Luohe Central Hospital,Luohe Henan 462300,China;Henan University of Chinese Medicine,Zhengzhou Henan 450002,China)

机构地区：[1]漯河市中心医院,河南漯河462300 [2]河南中医药大学,河南郑州450002

出　　处：《新中医》2025年第7期21-30,共10页New Chinese Medicine

基　　金：河南省高等学校重点科研项目(22A360005)。

摘　　要：目的:基于网络药理学和实验验证探讨桃红饮治疗动脉粥样硬化(AS)的作用机制。方法:利用中药系统药理学数据库与分析平台(TCMSP)获得桃红饮的活性成分及靶标,通过蛋白质相互作用(PPI)分析筛选桃红饮治疗AS的潜在活性成分及核心靶标,并对核心靶标进行基因本体(GO)及基因组百科全书(KEGG)通路富集分析,采用Cytoscape软件构建“疾病-中药-成分-核心靶点”多维关联可视化网络,获得桃红饮治疗AS的关键活性成分及靶标;采用AutoDock软件对部分化合物及靶标进行分子对接。利用ApoE^(-/-)雄性小鼠高脂饮食喂养建立AS模型,采用桃红饮干预进行实验验证。结果:共获得桃红饮37个活性成分,603个靶标,获得桃红饮干预AS的靶标92个,核心靶标23个,主要为白细胞介素-17(IL-17)、白细胞介素-6(IL-6)、肿瘤坏死因子(TNF)、白细胞介素-1β(IL-1β)、重组人趋化因子8(CXCL8)、基质金属蛋白酶9(MMP9)、细胞间黏附分子-1(ICAM-1)等。关键通路为辅助性T细胞17(Th17)免疫调节信号通路、IL-17信号通路等。分子对接结果显示关键化合物赤霉素7、常春藤皂苷元、木犀草素、洋川芎醌、恩比宁等5种活性成分和关键靶标(CXCL8、MMP9、IL-1β、IL-6)分子对接良好。动物实验发现,桃红饮能够抑制小鼠主动脉管腔内动脉粥样硬化斑块形成,降低血清甘油三酯(TG)、胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平和血清IL-1β、IL-6水平,调控核心靶点CXCL8、MMP9的表达。结论:桃红饮中赤霉素7、常春藤皂苷元、木犀草素、洋川芎醌、恩比宁等成分能够作用于IL-1β、IL-6、CXCL8、MMP9等靶点,其机制可能与IL-17信号通路调节有关。Objective:To explore the mechanism of action of Taohong Decoction in the treatment of atherosclerosis(AS)based on network pharmacology and experimental validation.Methods:The active components and targets of Taohong Decoction were obtained using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP).The potential active components and core targets of Taohong Decoction in treating AS were screened through protein-protein interaction(PPI)analysis.The core targets were subjected to Gene Ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway enrichment analysis.The"diseasemedicinals-component-core target"multi-dimensional association visualization network was constructed using Cytoscape software to obtain the key active components and targets of Taohong Decoction in treating AS.Molecular docking of some compounds and targets was performed using AutoDock software.An AS model was established by feeding ApoE^(-/-)male mice with a high-fat diet,and Taohong Decoction intervention was used for experimental validation.Results:A total of 37 active components and 603 targets of Taohong Decoction were obtained,with 92 targets for Taohong Decoction intervention in AS and 23 core targets,mainly including interleukin-17(IL-17),interleukin-6(IL-6),tumor necrosis factor(TNF),interleukin-1β(IL-1β),recombinant human chemokine 8(CXCL8),matrix metalloproteinase 9(MMP9),and intercellular adhesion molecule-1(ICAM-1).The key pathways were the Th17 immune regulation signaling pathway and the IL-17 signaling pathway.Molecular docking results showed that the key compounds gibberellin 7,hederagenin,luteolin,ligustrazine,and emodin,among five active components,had good molecular docking with key targets(CXCL8,MMP9,IL-1β,and IL-6).Animal experiments found that Taohong Decoction could inhibit the formation of atherosclerotic plaques in the aortic lumen of mice,reduce the levels of serum triglyceride(TG),cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),IL-1β,and IL-6,and regulate th

关 键 词：动脉粥样硬化 桃红饮 网络药理学 分子对接 动物实验 小鼠 

分 类 号：R285[医药卫生—中药学]